Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Palatin Technologies reports revenue challenges but advances pipeline programs

Palatin Technologies faced revenue challenges in Q3 2024 but showcased strengths in pipeline advancements and positive clinical results.
The company's financial performance improved despite increased operating expenses, with a focus on expanding clinical programs and enhancing drug profiles.
While facing cash utilization concerns and upcoming study expenses, Palatin remains optimistic about its progress and future milestones.

Palatin Technologies reports Q4 loss, progresses in ocular treatments

Palatin Technologies navigated Q4 2024 with a focus on cost reduction and asset sales, impacting revenue and expenses.
Despite financial challenges, the company's progress in ocular programs and pipeline development showcases strategic advancements.
Opportunities lie in leveraging asset sale proceeds, advancing clinical programs, and addressing funding needs for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED) – Topline Data Expected in February Oral PL8177 Phase 2 Clinical Study in Patients with Ulcerative Colitis  – Interim Analysis Expected in 2Q Calendar Year 2024 – Topline Results Expected in 2H Calendar Year 2024 BMT 701 Phase 2 BREAKOUT study in patients with diabetic kidney disease – Topline results expected in the second quarter of calendar year 2024 Obesity: Combination of an MCR4 Agonist + glucagon like peptide-1 (GLP-1) – Phase 2 Clinical Study Targeted to Start 1Q Calendar Year  2024 Male Sexual Dysfunction: B remelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients that do not Respond to PDE5i Monotherapy – Phase 2 Clinical Study Targeted to Start 1Q Calendar Year  2024 Vyleesi® Completed Asset Sale to Cosette Pharmaceuticals for up to $171 Million – $12 Million Upfront / Up to $159 Million in Sales-Based Milestones Closed on Gross Proceeds of $15 Million in Equity Teleconference and Webcast to be held on February 15, 2024, at 11:00 AM ET CRANBURY, N.J. , Feb. 15, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal second quarter ended December 31, 2023.

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

CRANBURY, N.J. , Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets.

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

Top-Line Results Expected in February CRANBURY, N.J. , Feb. 5, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced database lock for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Agenus

AST SpaceMobile

Microvast Holdings

PASSAGE BIO

Pixelworks

Quantum Computing

Stay on the Internet long enough – and it won't take too long, believe me – and you'll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns to outright conspiracy theories, the suits on Wall Street don't always get the love from retail investors.

7 Analyst-Backed Stocks With Promising 10-Bagger Potential

CRANBURY, N.J. , Feb. 1, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced registered direct offering of 1,831,503 shares of its common stock, at a purchase price of $5.46 per share of common stock.

Palatin Announces Closing of $10 Million Registered Direct Offering

CRANBURY, N.J. , Jan. 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 1,831,503 shares of its common stock, at a purchase price of $5.46 per share of common stock.

Palatin Announces $10 Million Registered Direct Offering

Clearsign Combustion

FiscalNote Holdings Inc

After four long years of volatility and economic uncertainty, there finally appears to be light at the end of the tunnel heading into 2024. As rates start coming down and monetary policy loosens, we could see significant tailwinds for beaten-down penny stocks primed for a rebound.

3 Penny Stocks to Buy to Unlock 2,500% Upside Potential

Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 Study Data Base Lock 2H January 2024 Topline Data Readout Expected Early 1Q Calendar Year 2024 Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Study in Active UC Patients Interim Analysis Data Readout on Track for 1Q Calendar Year 2024 Topline Results Expected in 2Q Calendar Year 2024 Obesity: Melanocortin Receptor 4 (MCR4) Agonist + Glucagon Like Peptide-1 (GLP-1) Phase 2 Clinical Study Targeted to Start 1Q Calendar Year 2024 Topline Results Expected in 2H Calendar Year 2024 Male Sexual Dysfunction: Bremelanotide Co-Formulated with a PDE5i for the Treatment of Erectile Dysfunction (ED) in Patients that do not Respond to PDE5i Monotherapy Phase 2 Clinical Study Targeted to Start 1Q Calendar Year 2024 Topline Results Expected in 2H Calendar Year 2024 Vyleesi® Completed Asset Sale to Cosette Pharmaceuticals for up to $171 Million $12 Million Upfront Plus Sales-Based Milestones of up to $159 Million CRANBURY, N.J. , Jan. 8, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today provided a corporate update, highlighted the Company's key calendar year 2023 accomplishments and outlined its anticipated calendar year 2024 clinical development milestones.

Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #HSDD--Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Terran Orbital Corp

Usio Inc

Wall Street analysts can get a bit optimistic with their price targets. So when I see calls for triple-digit upside, I take them with a grain of salt.

Analysts Say 3 Stocks Have a Combined Upside of 3000%

New York, December 21, 2023 – Palatin Technologies, Inc. (NYSE American: PTN) has completed the sale of Vyleesi® to Cosette Pharmaceuticals, a US-based, specialty pharmaceutical company, for up to $171 million. Vyleesi is the first and only as-needed FDA-approved treatment for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

Palatin Technologies Sells Vyleesi in $171M Transaction

Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million Palatin's focus is solely on its development and clinical pipeline based on the melanocortin receptor system CRANBURY, N.J., Dec. 20, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the sale of Vyleesi ® to Cosette Pharmaceuticals, a US-based, speciality pharmaceutical company, for up to $171 million, consisting of an upfront purchase price of $12 million plus contingent, sales-based milestone payments of up to $159 million.

Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million

CRANBURY, N.J. , Dec. 18, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") approving Palatin's plan (the "Plan") to come into compliance with the Exchange's continued listing standards under Section 1003(a)(i) and (ii) of the NYSE American Company Guide.

Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

Palatin Technologies, Inc. (NYSE:PTN ) Q1 2024 Earnings Conference Call November 14, 2023 11:00 AM ET Company Participants Carl Spana – President and Chief Executive Officer Steve Wills – Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Joe Pantginis – H.C. Wainwright Operator Greetings.

Palatin Technologies, Inc. (PTN) Q1 2024 Earnings Call Transcript

Enrollment Complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) 570 Patients Enrolled Topline Data Currently Expected Late 4Q Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Interim Analysis Targeted for 1Q Calendar Year 2024 Topline Results Currently Expected in 2Q Calendar Year 2024 Vyleesi® Gross Product Revenue Increased 11% Over the Prior Quarter Net Product Revenue Increased 20% Over the Prior Quarter Prescriptions Dispensed Increased 14% Over the Prior Quarter 7 Consecutive Quarters of Double-Digit Growth Teleconference and Webcast to be held November 14, 2023, at 11:00 AM EST CRANBURY, N.J. , Nov. 14, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal first quarter ended September 30, 2023, and provided a corporate update.

Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

CRANBURY, N.J. , Nov. 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before the open of the U.S. financial markets.

Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023

CRANBURY, N.J. , Oct. 24, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced registered direct offering of 2,358,491 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $2.12 per share of common stock (or common stock equivalents in lieu thereof).

Palatin Announces Closing of $5 Million Registered Direct Offering

CRANBURY, N.J. , Oct. 23, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with an institutional investor for the issuance and sale of an aggregate of 2,358,491 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $2.12 per share of common stock (or common stock equivalents in lieu thereof).

Palatin Announces $5 Million Registered Direct Offering

7 Consecutive Quarters of Double-Digit Growth in Product Revenue and Prescriptions Dispensed $4.6 million in Gross Product Revenue 11% growth over prior quarter; 100% growth over comparable quarter last year $2.1 million in Net Product Revenue 18% growth over prior quarter; 137% growth over comparable quarter last year  Prescriptions Dispensed 14% growth over prior quarter; 88% growth over comparable quarter last year  CRANBURY, N.J. , Oct. 19, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced preliminary fiscal year 2024 first quarter ended September 30, 2023 results, for Vyleesi® product revenue.

Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results

Positive data with Palatin's melanocortin-4 receptor (MC4R) agonist plus glucagon like peptide-1 (GLP-1) presented at the Peptide Therapeutics Symposium GLP-1 & MC4R agonist co-administration data shows increased weight loss and greater glucose control above monotherapy Preclinical data and prior clinical studies support the further clinical development and commercial potential of Palatin's melanocortin agonists for obesity Clinical study currently expected to start 1Q calendar year 2024 CRANBURY, N.J. , Oct. 18, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced plans to initiate a clinical study of melanocortin 4 receptor (MC4R) agonist, bremelanotide, an FDA approved product and 100% owned by Palatin, in combination with a Glucagon Like Peptide-1 (GLP-1) agonist, in obese patients in the first quarter of calendar year 2024.

Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

Data demonstrates oral PL8177 causes diseased colons to move to a healthier state Provides further support for ongoing oral PL8177 Phase 2 ulcerative colitis study CRANBURY, N.J. , Oct. 16, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of a poster entitled Cellular and Molecular Impact of the Melanocortin Receptor Agonist PL8177 in DSS Induced Colitis in Rats  at  the United European Gastroenterology Week (UEG) being held October 14-17 2023 in Copenhagen, Denmark.

Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment

Palatin Technologies, Inc. (NYSE:PTN ) Q4 2023 Earnings Conference Call September 28, 2023 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co., LLC Michael Higgins - Ladenburg Thalmann & Co. Inc. Operator Greetings, and welcome to Palatin's Fourth Quarter and Fiscal Year End 2023 Operating Results Conference Call.

Palatin Technologies, Inc. (PTN) Q4 2023 Earnings Call Transcript

Enrollment in Phase 3 PL9643  MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled Topline Data Expected Late 4Q Calendar Year 2023 Interim Analysis of Initial 120 Patients Showed  Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye  Excellent Patient Safety and Tolerability  Product Profile Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis  Interim Analysis Targeted for 1Q Calendar Year 2024 Topline Results Currently Expected First Half Calendar Year 2024 Vyleesi® Net Product Revenue Increased 47% Over the Prior Quarter Prescriptions Dispensed Increased 16% Over the Prior Quarter 6 Consecutive Quarters of Double-Digit Growth Teleconference and Webcast to be held on September 28, 2023, at 11:00 AM ET CRANBURY, N.J. , Sept. 28, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal fourth quarter and fiscal year ended June 30, 2023.

Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update

CRANBURY, N.J. , Sept. 22, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets.

Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023

CRANBURY, N.J. , Sept. 7, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will present at H.C.

News for Palatin Technologies Stock (PTN)